The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's disease.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-02-14 DOI:10.1016/j.medj.2024.100572

Maria Cappello, Ciro Celsa

引用次数: 0

Abstract

The VIVID-1 study is a phase 3 randomized controlled trial assessing the efficacy and safety of mirikizumab in moderate-to-severe active Crohn's disease.¹ The study confirms the advantage of selective IL-23 inhibition, while the treat-through design and the choice of composite coprimary endpoints represent an innovative strategy in conducting clinical trials in Crohn's disease.

查看原文本刊更多论文

VIVID-1 研究：一种新颖的方法进一步证明了选择性抑制 IL-23 对克罗恩病的疗效。

VIVID-1研究是一项3期随机对照试验，评估mirikizumab治疗中重度活动性克罗恩病的疗效和安全性该研究证实了选择性IL-23抑制的优势，而穿透治疗设计和复合主要终点的选择代表了克罗恩病临床试验的创新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.